Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Pulmonary Delivery of Levamisole Nanoparticles As an Immunomodulator Affecting Th and a Potential Adam10 Inhibitor to Ameliorate Severe Allergic Asthma Publisher Pubmed



Fang L1 ; Nikfarjam N2 ; Gharagozlou M3 ; Huang T4 ; Song Y1 ; Islambulchilar Z5 ; Esmaeilzadeh A6 ; Jafari D6 ; Athari SS6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Respiratory and Critical Care Medicine, Xi'an People's Hospital (Xi'an Fourth Hospital), 155 East Aerospace Road, Shaanxi, Xi'an, 710100, China
  2. 2. Department of Chemistry, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, 45137-66731, Iran
  3. 3. Department of Pediatrics, School of Medicine, Children's Medical Center, Tehran University of Medical Sciences, Tehran, 1416753955, Iran
  4. 4. Department of Orthopedics, The First Affiliated Hospital of Xi'an Medical University, 48 West Fengho Road, Lianhu District, Shaanxi, Xi'an, 710000, China
  5. 5. Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, 5166/15731, Iran
  6. 6. Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, 45371-38111, Iran

Source: ACS Biomaterials Science and Engineering Published:2022


Abstract

Asthma is a common chronic lung disease without absolute treatment, and hypersensitivity reactions and type 2 immune responses are responsible for asthma pathophysiology. ADAM10 as a metalloproteinase transmembrane protein is critical for development of Th2 responses, and levamisole as an anthelmintic drug has immunomodulatory effects, which not only regulates ADAM10 activity but also can suppress the bone marrow and neutrophil production. Therefore, in the present study, nanoparticles were used as a levamisole delivery system to reduce bone marrow suppression, and the immunomodulatory and ADAM10 inhibitory effects of levamisole were studied in allergic asthma. Asthmatic mice were treated with PLGA-levamisole nanoparticles. Then, AHR, BALF, and blood cell counts, levels of the IgG1 subclass, total and OVA-specific IgE, IL2, IL-4, IL-5, IL-10, IL-13, IL-17, IL-25, IL-33, INF-γ, and TNF-α, gene expression of FoxP3, T-bet, RORγt, PU.1, GATA3, FcϵRII, CysLT1R, eotaxin, and ADAM10, and lung histopathology were evaluated. PLGA-LMHCl with considered characteristics could control airway hyper-responsiveness, eosinophils in the BALF, levels of immunoglobulins, Th2-, Th9-, and Th17-derived cytokines and pivotal genes, eosinophilic inflammation, hyperplasia of the goblet cell, and hyperproduction of mucus and could increase Th1- and Treg-derived cytokines and also pivotal genes. It could also modulate the ADAM10 activity and had no effect on the number of neutrophils in the bloodstream. The novel safe nanodrug had no side effect on the bone marrow to produce neutrophils and could control the allegro-immuno-inflammatory response of asthma. © 2022 American Chemical Society. All rights reserved.